DE04010435T1 - Zolpidem Hemitartrat Solvat - Google Patents

Zolpidem Hemitartrat Solvat Download PDF

Info

Publication number
DE04010435T1
DE04010435T1 DE04010435T DE04010435T DE04010435T1 DE 04010435 T1 DE04010435 T1 DE 04010435T1 DE 04010435 T DE04010435 T DE 04010435T DE 04010435 T DE04010435 T DE 04010435T DE 04010435 T1 DE04010435 T1 DE 04010435T1
Authority
DE
Germany
Prior art keywords
zolpidem hemitartrate
hydrate
solvate
zolpidem
hemitartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE04010435T
Other languages
German (de)
English (en)
Inventor
Judith Aronhime
Ben-Zion Dolitzky
Marco Kordova
David Leonov
Erzebet Meszaros-Sos
Szaboles Salyi
Anchel Schwartz
Csaba Szabo
Shlomo Zavurov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE04010435(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE04010435T1 publication Critical patent/DE04010435T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Amplifiers (AREA)
  • Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
DE04010435T 2000-04-24 2001-04-24 Zolpidem Hemitartrat Solvat Pending DE04010435T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19929800P 2000-04-24 2000-04-24
US199298P 2000-04-24
US20602500P 2000-05-22 2000-05-22
US206025P 2000-05-22
US22536400P 2000-08-14 2000-08-14
US225364P 2000-08-14

Publications (1)

Publication Number Publication Date
DE04010435T1 true DE04010435T1 (de) 2005-09-01

Family

ID=27394001

Family Applications (7)

Application Number Title Priority Date Filing Date
DE04010435T Pending DE04010435T1 (de) 2000-04-24 2001-04-24 Zolpidem Hemitartrat Solvat
DE60122216T Expired - Fee Related DE60122216T2 (de) 2000-04-24 2001-04-24 Zolpidem Hemitartrat Solvat
DE04010651T Pending DE04010651T1 (de) 2000-04-24 2001-04-24 Mikronisiertes Zolpidem-Hemitartrat
DE60114617T Expired - Fee Related DE60114617T2 (de) 2000-04-24 2001-04-24 Zolpidem hemitartrat
DE60125429T Expired - Fee Related DE60125429T2 (de) 2000-04-24 2001-04-24 Zolpidem hemitartrat solvat
DE60122944T Expired - Fee Related DE60122944T2 (de) 2000-04-24 2001-04-24 Mikronisiertes Zolpidem-Hemitartrat
DE20122435U Expired - Lifetime DE20122435U1 (de) 2000-04-24 2001-04-24 Mikronisiertes Zolpidem-Hemitartrat

Family Applications After (6)

Application Number Title Priority Date Filing Date
DE60122216T Expired - Fee Related DE60122216T2 (de) 2000-04-24 2001-04-24 Zolpidem Hemitartrat Solvat
DE04010651T Pending DE04010651T1 (de) 2000-04-24 2001-04-24 Mikronisiertes Zolpidem-Hemitartrat
DE60114617T Expired - Fee Related DE60114617T2 (de) 2000-04-24 2001-04-24 Zolpidem hemitartrat
DE60125429T Expired - Fee Related DE60125429T2 (de) 2000-04-24 2001-04-24 Zolpidem hemitartrat solvat
DE60122944T Expired - Fee Related DE60122944T2 (de) 2000-04-24 2001-04-24 Mikronisiertes Zolpidem-Hemitartrat
DE20122435U Expired - Lifetime DE20122435U1 (de) 2000-04-24 2001-04-24 Mikronisiertes Zolpidem-Hemitartrat

Country Status (21)

Country Link
US (8) US20020077332A1 (enExample)
EP (1) EP1292304B1 (enExample)
JP (3) JP2003531173A (enExample)
KR (1) KR20030069796A (enExample)
AT (4) ATE335481T1 (enExample)
AU (2) AU2001257213B2 (enExample)
CA (1) CA2406982A1 (enExample)
CZ (1) CZ20023775A3 (enExample)
DE (7) DE04010435T1 (enExample)
DK (1) DK1292304T3 (enExample)
ES (4) ES2277301T3 (enExample)
HR (1) HRP20020909A2 (enExample)
HU (1) HUP0300701A2 (enExample)
IL (1) IL152411A0 (enExample)
NZ (1) NZ522015A (enExample)
PL (1) PL358548A1 (enExample)
PT (3) PT1473036E (enExample)
SE (1) SE5292304T3 (enExample)
SK (1) SK16372002A3 (enExample)
WO (1) WO2001080857A1 (enExample)
YU (1) YU79402A (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284322A1 (en) 2000-08-29 2002-03-13 Ranbaxy Laboratories Limited Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003297153B2 (en) 2002-12-18 2010-06-10 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
WO2004087703A1 (en) * 2003-03-12 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of n,n,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide
WO2005010002A1 (en) * 2003-07-31 2005-02-03 Ranbaxy Laboratories Limited Process for the synthesis of zolpidem
KR20130116378A (ko) * 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
WO2006008636A2 (en) * 2004-07-16 2006-01-26 Ranbaxy Laboratories Limited Processes for the preparation of zolpidem and its hemitartrate
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20060281783A1 (en) * 2005-05-25 2006-12-14 Transoral Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
MX2008001778A (es) * 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
BRPI0615357A2 (pt) * 2005-08-19 2011-05-17 Aventis Pharma Inc combinação de um agente hipnótico e r (+)-alfa-(2,3-dimetóxi-fenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e aplicação terapêutica do mesmo
WO2007040995A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
EP1948134A2 (en) * 2005-10-17 2008-07-30 Mallinckrodt, Inc. Polymorph transformation of zolpidem in tablet matrix
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
RS51423B (sr) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. Benzoimidazol-2-il pirimidini i pirazini kao modulatori histaminskog h4 receptora
US20080132535A1 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized Zolpidem Pharmaceutical Compositions
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
TW201018668A (en) * 2008-06-30 2010-05-16 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
ES2754398T3 (es) 2009-11-27 2020-04-17 Genzyme Corp Eliglustat (Genz 112638) como inhibidor de glucosilceramida-sintasa para uso en un método de tratamiento de la enfermedad de fabry o de gaucher, comprendiendo el método ajustar la dosis terapéutica individual al metabolismo P-450 del paciente
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
CN116283957A (zh) * 2021-12-03 2023-06-23 山东新时代药业有限公司 唑吡坦水合物及其制备方法
CN116283958A (zh) * 2021-12-03 2023-06-23 山东新时代药业有限公司 唑吡坦共晶体及其制备方法
CN117907368A (zh) * 2024-01-27 2024-04-19 鲁南贝特制药有限公司 一种酒石酸唑吡坦药用晶型d中晶型a、e的定量测定方法
CN118750459B (zh) * 2024-07-22 2025-04-01 常州市武进中医医院 一种酒石酸唑吡坦片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
DE3018940A1 (de) * 1980-05-17 1981-11-26 Hoechst Ag, 6000 Frankfurt Verwendung eines vinylchlorid-pfropf-copolymerisates in der plastisolverarbeitung
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525601A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4675323A (en) * 1985-08-06 1987-06-23 Synthelabo Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
FR2600650B1 (fr) * 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) * 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
DE3865073D1 (de) * 1987-03-27 1991-10-31 Synthelabo Imidazopyridinderivate, ihre herstellung und therapeutische verwendung.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
IT1276522B1 (it) * 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
PT1163241E (pt) * 1999-03-25 2005-08-31 Synthon Bv Sais de zolpidem
PT1038875E (pt) * 1999-03-25 2003-10-31 Synthon Bv Derivados de imidazopiridina e processo para os preparar
WO2001042239A1 (en) * 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound

Also Published As

Publication number Publication date
US20040214859A1 (en) 2004-10-28
AU5721301A (en) 2001-11-07
DE60125429D1 (de) 2007-02-01
DE04010651T1 (de) 2005-09-01
EP1292304B1 (en) 2005-11-02
PT1475093E (pt) 2006-11-30
AU2001257213B2 (en) 2005-09-29
JP2003531173A (ja) 2003-10-21
EP1292304A4 (en) 2003-07-23
ATE308324T1 (de) 2005-11-15
DE60122216T2 (de) 2007-08-30
DK1292304T3 (da) 2005-12-19
DE60122944T2 (de) 2007-04-12
EP1292304A1 (en) 2003-03-19
HRP20020909A2 (en) 2004-08-31
ES2238941T1 (es) 2005-09-16
DE20122435U1 (de) 2005-10-06
WO2001080857A9 (en) 2002-06-27
DE60114617D1 (de) 2005-12-08
CA2406982A1 (en) 2001-11-01
US20040214858A1 (en) 2004-10-28
ATE335481T1 (de) 2006-09-15
US20040220211A1 (en) 2004-11-04
US20020077332A1 (en) 2002-06-20
DE60114617T2 (de) 2006-07-27
SK16372002A3 (sk) 2003-04-01
ES2239558T1 (es) 2005-10-01
US20040220210A1 (en) 2004-11-04
ATE348613T1 (de) 2007-01-15
SE5292304T3 (enExample) 2005-11-02
WO2001080857A1 (en) 2001-11-01
DE60125429T2 (de) 2007-09-27
ATE338550T1 (de) 2006-09-15
DE60122944D1 (de) 2006-10-19
CZ20023775A3 (cs) 2003-10-15
JP2006249105A (ja) 2006-09-21
DE60122216D1 (de) 2006-09-21
NZ522015A (en) 2004-08-27
JP2006137778A (ja) 2006-06-01
US20070037843A1 (en) 2007-02-15
KR20030069796A (ko) 2003-08-27
IL152411A0 (en) 2003-05-29
ES2239558T3 (es) 2007-04-01
HUP0300701A2 (hu) 2003-07-28
ES2277301T3 (es) 2007-07-01
PL358548A1 (en) 2004-08-09
PT1473036E (pt) 2006-10-31
US20040220212A1 (en) 2004-11-04
YU79402A (sh) 2006-03-03
ES2238941T3 (es) 2007-04-01
PT1541146E (pt) 2007-01-31
ES2248321T3 (es) 2006-03-16
US20040220213A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
DE04010435T1 (de) Zolpidem Hemitartrat Solvat
DE2904445C2 (de) N↓1↓-(4-Amino-6.7-dimethoxy-2-chinazolyl)-N↓1↓-methyl-N↓2↓-(2-tetrahydrofuroyl)-1.3-propandiamin, seine Herstellung und seine pharmazeutische Verwendung
DE69910795T2 (de) Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
DE69823648T2 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
EP2266621A3 (de) Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE74584T1 (de) Langwirkende mehrschichttablette.
EP1916254A3 (de) 17alpha-Alkyl-17beta-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17beta-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE247983T1 (de) Arzneizubereitung zur oralen anwendung.
CH616668A5 (enExample)
AT3185U2 (de) Paroxetinmethansulfonat
DE69230314T2 (de) Cytokinhemmer
CH668184A5 (de) Verwendung von acyloxyalkanoylcholinsalzen fuer die herstellung eines mittels zur besserung und therapie von neuropsychiatrischen symptomen, die die demenz begleiten.
EP0286928A3 (de) Neue 2-Acylpyrrolidin-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel sowie deren Verwendung
DE60123528T2 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
AT344151B (de) Verfahren zur herstellung von neuen naphthalinderivaten
EP0236838A3 (de) Aminoester-Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung
DE1901519A1 (de) Chinazolinylharnstoffe
DE2034640C3 (de) l-p-(7-Trifluormethyl-4-chinolyl) -amino-benzoyl-piperazine, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Bluthochdruck
DE69816832T2 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
DE04758472T1 (de) Verfahren zur herstellung eines pharmazeutischen wirkstoffs mit hochspezifischer oberfläche
US3256149A (en) Compositions comprising an alkaloid of mitragyna speciosa and methods of using same
DE382180T1 (de) Derivate von thiazolidin-4-carbonsaeure, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
AT330748B (de) Verfahren zur herstellung von neuen 1- phenoxy-2-hydroxy-3-propargylaminopropanen und von deren saureadditionssalzen
DE69007439T2 (de) Mittel gegen Tumore.